2. Search Result
Search Result
Results for "

Antisecretory activity

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

3

Peptides

3

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-15538
    Ebrotidine

    FI3542

    		 Histamine Receptor Inflammation/Immunology Endocrinology
    Ebrotidine(FI 3542) is a competitive H2-receptor antagonist (Ki= 127.5 nM) with a potent antisecretory activity and evidenced gastroprotection.
    Ebrotidine
  • HY-N7031
    (±)​-​Vasicine

    (±)​-Peganine

    		 Proton Pump Inflammation/Immunology
    (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H +-K +-ATPase activity?in vitro?with an IC50 of 73.47?μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and?cytoprotective?effect .
    (±)​-​Vasicine
  • HY-B1806A
    Tridihexethyl chloride

    Pathilon chloride

    		 mAChR Neurological Disease Inflammation/Immunology
    Tridihexethyl (Pathilon) chloride is an orally active anticholinergic agent and mAChR antagonist, shows activities of antimuscarinic and anticholinergic. Tridihexethyl chloride shows pronounced antispasmodic and antisecretory effects on the gastrointestinal tract. Tridihexethyl chloride can be used in studies of peptic ulcer disease and acquired nystagmus .
    Tridihexethyl chloride
  • HY-15541
    Zaltidine

    CP-57361

    		 Histamine Receptor Endocrinology
    Zaltidine dihydrochloride (CP-5736 dihydrochloride) is a highly specific H2 receptor antagonist with antisecretion activity. Zaltidine dihydrochloride reduces the stimulant effect of histamine on gastric acid secretion by binding to histamine H2 receptors on gastric parietal cells, thus reducing gastric acid production. Zaltidine dihydrochloride can be used in the study of gastric acid-related diseases such as duodenal ulcers .
    Zaltidine
  • HY-N10763
    N-Methylcorydaldine

    		Others Endocrinology
    N-Methylcorydaldine, an alkaloid, shows promising anti-secretory activity .
    N-Methylcorydaldine
  • HY-19048
    CP-66948

    		Histamine Receptor Endocrinology
    CP-66948 is a histamine H2-receptor antagonist with gastric antisecretory activity and mucosal protective properties.
    CP-66948
  • HY-121406
    (Z)-Lafutidine

    (Z)-FRG-8813

    		 Histamine Receptor Inflammation/Immunology
    (Z)-Lafutidine ((Z)-FRG-8813) is a potent histamine H2 receptor antagonist. (Z)-Lafutidine shows anti-secretory and gastroprotective activities .
    (Z)-Lafutidine
  • HY-106347
    Itriglumide

    CR 2945

    		 Cholecystokinin Receptor Inflammation/Immunology
    Itriglumide (CR 2945) is an anthranilic acid derivative. Itriglumide is a potent and selective CCKB receptor antagonist, with an IC50 of 2.3 nM. Itriglumide antagonizes the response to gastrin in a dose-dependent manner with an IC50 of 5.9 nM. Itriglumide shows antisecretory and antiulcer activity .
    Itriglumide
  • HY-N7031R
    (±)​-​Vasicine (Standard)

    		Proton Pump Inflammation/Immunology
    (±)?-Vasicine (Standard) is the analytical standard of (±)?-Vasicine. This product is intended for research and analytical applications. (±)-Vasicine is the racemate of Vasicine. Vasicine (Peganine) significantly inhibits H+-K+-ATPase activity in vitro with an IC50 of 73.47 μg/mL. Anti-ulcer activity. Vasicine shows significant anti-secretory, antioxidant and cytoprotective effect .
    (±)​-​Vasicine (Standard)
  • HY-15541A
    Zaltidine dihydrochloride

    CP-5736 dihydrochloride

    		 Histamine Receptor Endocrinology
    Zaltidine (CP-5736) dihydrochloride is a highly specific H2 receptor antagonist with antisecretion activity. Zaltidine dihydrochloride reduces the stimulant effect of histamine on gastric acid secretion by binding to histamine H2 receptors on gastric parietal cells, thus reducing gastric acid production. Zaltidine dihydrochloride can be used in the study of gastric acid-related diseases such as duodenal ulcers .
    Zaltidine dihydrochloride
  • HY-79135
    Pasireotide ditrifluoroacetate
    Maximum Cited Publications
    6 Publications Verification

    SOM230 ditrifluoroacetate; Pasireotide TFA salt

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide ditrifluoroacetate
  • HY-120381
    PD 136450

    CAM 1189

    		 Cholecystokinin Receptor Neurological Disease Inflammation/Immunology
    PD 136450 (CAM 1189) is an antagonist for cholecystokinin 2 (CCK2). PD 136450 exhibits anti-secretory, anxiolytic and anti-ulcer activities, inhibits gastric acid secretion (IC50=1 mg/kg), and ameliorates the haemorrhagic lesions (IC50=4.7 mg/kg) in rats .
    PD 136450
  • HY-108768
    Pasireotide pamoate

    SOM230 pamoate

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) pamoate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide pamoate exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide pamoate
  • HY-16381B
    Pasireotide (diaspartate)

    SOM230 (diaspartate)

    		 Somatostatin Receptor Neurological Disease Cancer
    Pasireotide (SOM230) diaspartate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide diaspartate exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide (diaspartate)
  • HY-B0305A
    Roxatidine Acetate Hydrochloride

    HOE 760

    		 Histamine Receptor Metabolic Disease Inflammation/Immunology Cancer
    Roxatidine Acetate Hydrochloride is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine Acetate Hydrochloride has antisecretory potency against gastric acid secretion. Roxatidine Acetate Hydrochloride can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine Acetate Hydrochloride has antitumor activity .
    Roxatidine Acetate Hydrochloride
  • HY-B0305
    Roxatidine acetate

    		Histamine Receptor Metabolic Disease Inflammation/Immunology Cancer
    Roxatidine acetate is a potent, selective, competitive and orally active histamine H2-receptor antagonist. Roxatidine acetate has antisecretory potency against gastric acid secretion. Roxatidine acetate can also suppress inflammatory responses and can be used for gastric and duodenal ulcers research. Roxatidine acetate has antitumor activity .
    Roxatidine acetate
  • HY-15295
    Vonoprazan Fumarate
    5 Publications Verification

    TAK-438

    		 Proton Pump Metabolic Disease Cancer
    Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .
    Vonoprazan Fumarate
  • HY-79136
    Pasireotide L-aspartate salt
    Maximum Cited Publications
    6 Publications Verification

    SOM230 L-aspartate

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) L-aspartate salt, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide L-aspartate salt exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide L-aspartate salt
  • HY-100007A
    Vonoprazan hydrochloride

    TAK-438 hydrochloride

    		 Proton Pump Bacterial Infection Endocrinology Cancer
    Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .
    Vonoprazan hydrochloride
  • HY-17507
    Pantoprazole
    3 Publications Verification

    BY1023; SKF96022

    		 Proton Pump Autophagy Apoptosis Bacterial Inflammation/Immunology Cancer
    Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
    Pantoprazole
  • HY-17507A
    Pantoprazole sodium
    3 Publications Verification

    BY1023 sodium; SKF96022 sodium

    		 Proton Pump Autophagy Apoptosis Bacterial Inflammation/Immunology Cancer
    Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
    Pantoprazole sodium
  • HY-17507B
    Pantoprazole sodium hydrate
    3 Publications Verification

    BY1023 sodium hydrate; SKF96022 sodium hydrate

    		 Proton Pump Autophagy Apoptosis Bacterial Inflammation/Immunology Cancer
    Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
    Pantoprazole sodium hydrate
  • HY-100007
    Vonoprazan
    5 Publications Verification

    TAK-438 free base

    		 Proton Pump Bacterial Endocrinology Cancer
    Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan
  • HY-16381
    Pasireotide
    Maximum Cited Publications
    6 Publications Verification

    SOM230

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230), a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide also exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide
  • HY-16381A
    Pasireotide acetate
    Maximum Cited Publications
    6 Publications Verification

    SOM230 acetate

    		 Somatostatin Receptor Endocrinology Cancer
    Pasireotide (SOM230) acetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5, pKi=8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide acetate can suppress GH, IGF-I and ACTH secretion, indicating potential efficacy in acromegaly and Cushing's disease. Pasireotide acetate also exhibits antisecretory, antiproliferative, and proapoptotic activity .
    Pasireotide acetate
  • HY-17507S
    Pantoprazole-d6

    BY1023-d6; SKF96022-d6

    		 Isotope-Labeled Compounds Proton Pump Autophagy Apoptosis Inflammation/Immunology Cancer
    Pantoprazole-d6 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
    Pantoprazole-d6
  • HY-17507S1
    Pantoprazole-d3

    BY1023-d3; SKF96022-d3

    		 Isotope-Labeled Compounds Proton Pump Autophagy Apoptosis Inflammation/Immunology Cancer
    Pantoprazole-d3 is deuterium labeled Pantoprazole. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI)[1]. Pantoprazole, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142)[3][4].
    Pantoprazole-d3
  • HY-17507AR
    Pantoprazole (sodium) (Standard)

    BY1023 (sodium) (Standard); SKF96022 (sodium) (Standard)

    		 Proton Pump Autophagy Apoptosis Bacterial Inflammation/Immunology Cancer
    Pantoprazole (sodium) (Standard) is the analytical standard of Pantoprazole (sodium). This product is intended for research and analytical applications. Pantoprazole sodium (BY10232 sodium) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
    Pantoprazole (sodium) (Standard)
  • HY-17507R
    Pantoprazole (Standard)

    		Proton Pump Autophagy Apoptosis Bacterial Inflammation/Immunology Cancer
    Pantoprazole (Standard) is the analytical standard of Pantoprazole. This product is intended for research and analytical applications. Pantoprazole (BY10232) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole, a substituted benzimidazole, is a potent H +/K +-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
    Pantoprazole (Standard)
  • HY-17507BR
    Pantoprazole (sodium hydrate) (Standard)

    		Proton Pump Autophagy Apoptosis Bacterial Inflammation/Immunology Cancer
    Pantoprazole (sodium hydrate) (Standard) is the analytical standard of Pantoprazole (sodium hydrate). This product is intended for research and analytical applications. Pantoprazole sodium hydrate (BY10232 sodium hydrate) is an orally active and potent proton pump inhibitor (PPI) . Pantoprazole sodium hydrate, a substituted benzimidazole, is a potent H+/K+-ATPase inhibitor with an IC50 of 6.8 μM. Pantoprazole sodium hydrate improves pH stability and has anti-secretory, anti-ulcer activities. Pantoprazole sodium hydrate significantly increased tumor growth delay combined with Doxorubicin (HY-15142) .
    Pantoprazole (sodium hydrate) (Standard)
  • HY-100007R
    Vonoprazan (Standard)

    TAK-438 (Standard)

    		 Proton Pump Bacterial Endocrinology
    Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H +,K +-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .
    Vonoprazan (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: